Orion S.A. H1 Sales Surge 22%, Raises 2026 Profit Outlook
OEC sits 51% above its 52-week low of $4.345.
Summary
Orion S.A. reported H1 2026 net sales of EUR 939.3M, up 21.8% year-over-year, with operating profit jumping 59.6% to EUR 291.3M. Q2 alone saw sales of EUR 521.6M and operating profit of EUR 176.6M, driven by strong Innovative Medicines growth and higher Nubeqa® royalty income. The company raised the lower end of its 2026 operating profit guidance to EUR 650M from EUR 600M, while keeping the upper end at EUR 750M. This follows a Q1 marked by a net loss and declining EBITDA, making the sharp H1 recovery a significant positive surprise. Key pipeline progress includes ODM-212 entering Phase 1b/2 and receiving orphan drug designations, plus FDA approval of Tessie® for the Animal Health division. The balance sheet has strengthened dramatically, with interest-bearing net liabilities falling to EUR 2.5M from EUR 134.3M a year ago. The raised guidance and robust pipeline momentum suggest the turnaround is gaining traction.
At the time of this announcement, OEC was trading at $6.54 on NYSE in the Life Sciences sector, with a market capitalization of approximately $376.1M. The 52-week trading range was $4.35 to $11.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.